Medicamen Biotech Ltd develops and markets a wide range of branded and generic formulations in the pharmaceutical industry.
Financial Results:
Medicamen Biotech Ltd reported Revenues for Q1FY24 of ₹40.50 Crores up from ₹33.09 Crore year on year, a rise of 22.39%.
Total Expenses for Q1FY24 of ₹35.73 Crores up from ₹29.73 Crores year on year, a rise of 20.18%.
Consolidated Net Profit of ₹4.42 Crores up 23.12% from ₹3.59 Crores in the same quarter of the previous year.
The Earnings per Share is ₹3.49, up 18.71% from ₹2.94 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.